Roche Takes SCENIC Route On Genetic Modifiers
Deal Could Be Worth Up To $375m
The Dutch biotech's C-suite tells Scrip that the technology it has developed and now licensed to Genentech allows it to systematically go through the whole genome gene by gene and discover what the modifier of a particular disease is.
